Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.
Top Stages
1 past transactions
Creabilis
Acquisition in 2016
Creabilis is an emerging European specialty pharmaceutical company specializing in dermatology and focused on developing innovative treatments for skin disorders. The company is committed to addressing significant unmet medical needs in this area and has a strong track record in dermatological research. Creabilis has established a robust pipeline of clinical and pre-clinical drug candidates, including its lead product, CT327, which is a topical treatment for chronic pruritus and is set to enter Phase II clinical trials. Additionally, the company plans to build a pruritus franchise around CT327 and another candidate, CT340, both of which were developed using its proprietary Low Systemic Exposure platform technology. Through its innovative drug discovery programs, Creabilis aims to market these products directly or in partnership, reinforcing its position in the specialty pharmaceuticals sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.